During the past decade, Centro Estatal de Cancerología conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Estatal de Cancerología" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Janssen Research & Development, LLC" with 2 trials sponsored, "CTI BioPharma" with 1 trials sponsored, "Eisai Inc." with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Estatal de Cancerología" #1 collaborator was "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "PPD" with 1 trials as a collaborator and "SOLTI Breast Cancer Research Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Centro Estatal de Cancerología" are "Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials), "Colorectal Cancer" (1 trials), "Locally Advanced or Metastatic Breast Cancer" (1 trials) and "Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Centro Estatal de Cancerología" in a lesser frequency.

Most popular intervention types in "Centro Estatal de Cancerología" are "Drug" (10 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "Docetaxel" (2 trials), "5-Fluorouracil (5-FU)" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials) and "Erdafitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Estatal de Cancerología" are 7 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Centro Estatal de Cancerología". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Centro Estatal de Cancerología, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Estatal de Cancerología, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".